Latest Breaking News On - News ratings for reata pharmaceuticals daily - Page 4 : comparemela.com

Reata Pharmaceuticals (NASDAQ:RETA) Earns Neutral Rating from Cantor Fitzgerald

Reata Pharmaceuticals (NASDAQ:RETA) Earns Neutral Rating from Cantor Fitzgerald
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

Bhaskar anandCarter birAnalyst recommendations for reata pharmaceuticalsReata pharmaceuticals price performanceInsider activity at reata pharmaceuticalsReata pharmaceuticals incReata pharmaceuticalsUs bancorpJefferies financial groupNews ratings for reata pharmaceuticals dailyMetlife investment managementSecurities exchange commissionJpmorgan chase coCantor fitzgeraldYork mellon corpVanguard group inc

Reata Pharmaceuticals (NASDAQ:RETA) Receives New Coverage from Analysts at StockNews com

Reata Pharmaceuticals (NASDAQ:RETA) Receives New Coverage from Analysts at StockNews com
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

Bhaskar anandRobertw bairdCarter birNisa investment advisorsReata pharmaceuticals incAnalyst recommendations for reata pharmaceuticalsCantor fitzgeraldReata pharmaceuticals tradingInsider transactions at reata pharmaceuticalsSecurities exchange commissionNews ratings for reata pharmaceuticals dailyInternational assets investment managementChina universal asset management coReata pharmaceuticalsReata pharmaceuticals company profileBelpointe asset management

StockNews com Begins Coverage on Reata Pharmaceuticals (NASDAQ:RETA)

StockNews com Begins Coverage on Reata Pharmaceuticals (NASDAQ:RETA)
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

Robertw bairdManmeet singh soniBhaskar anandStifel nicolausReata pharmaceuticals incAnalyst recommendations for reata pharmaceuticalsReata pharmaceuticals price performanceChina universal asset management coCantor fitzgeraldReata pharmaceuticalsSecurities exchange commissionFinancial services group incStifel financial corpInstitutional trading of reata pharmaceuticalsNews ratings for reata pharmaceuticals dailyReata pharmaceuticals company profile

Cantor Fitzgerald Weighs in on Reata Pharmaceuticals, Inc s FY2023 Earnings (NASDAQ:RETA)

Cantor Fitzgerald Weighs in on Reata Pharmaceuticals, Inc s FY2023 Earnings (NASDAQ:RETA)
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

Carter birBhaskar anandHedge funds weigh in on reata pharmaceuticalsJpmorgan chase coJefferies financial groupReata pharmaceuticalsNews ratings for reata pharmaceuticals dailyMetlife investment managementReata pharmaceuticals company profileCantor fitzgeraldReata pharmaceuticals incVanguard group incReata pharmaceuticals price performanceUs bancorpYork mellon corpFree report

Cantor Fitzgerald Reiterates Neutral Rating for Reata Pharmaceuticals (NASDAQ:RETA)

Reata Pharmaceuticals (NASDAQ:RETA – Get Free Report)‘s stock had its “neutral” rating reaffirmed by equities researchers at Cantor Fitzgerald in a research note issued to investors on Tuesday, Benzinga reports. They presently have a $172.00 price target on the stock. Cantor Fitzgerald’s target price indicates a potential upside of 1.73% from the company’s previous close. […]

New zealand generalNew zealandLeerink partnrsManmeet singh soniCarter birFirst light asset managementBlackrock incAnalyst recommendations for reata pharmaceuticalsReata pharmaceuticals stockReata pharmaceuticals incSecurities exchange commissionPerceptive advisorsHedge funds weigh in on reata pharmaceuticalsCantor fitzgeraldJefferies financial groupVanguard group inc